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A B S T R A C T
Background: Tumor location is important for surgical decision making. Particular attention is paid to regions
that contain sensorimotor and language functions, but it is unknown if these are the most important regions from
the patients' perspective.
Objective: To develop an atlas for depicting and assessing the potential importance of tumor location for peri-
operative health-related quality of life (HRQoL) in patients with newly diagnosed high-grade glioma.
Methods: Patient-reported HRQoL data and semi-automatically segmented preoperative 3D MRI-images were
combined in 170 patients. The images were registered to a standardized space where the individual tumors were
given the values and color intensity of the corresponding HRQoL. Descriptive brain maps of HRQoL, defined
quantitative analyses, and voxel-based lesion symptom mapping comparing patients with tumors in different
locations were made.
Results: There was no statistical difference in overall perioperative HRQoL between patients with tumors located
in left or right hemisphere, between patients with tumors in different lobes, or between patients with tumors
located in non-eloquent, near eloquent, or eloquent areas. Patients with tumors involving the internal capsule,
and patients with preoperative motor symptoms and postoperative motor deficits, reported significantly worse
overall HRQoL-scores.
Conclusions: The impact of anatomical tumor location on overall perioperative HRQoL seems less than fre-
quently believed, and the distinction between critical and less critical brain regions seems more unclear ac-
cording to the patients than perhaps when judged by physicians. However, worse HRQoL was found in patients
with tumors in motor-related regions, indicating that these areas are crucial also from the patients' perspective.
1. Introduction
Diffuse glioma is the most common primary malignant brain tumor
in adults (Ostrom et al., 2017). The surgical aim is to achieve maximal
“safe” resection, which is a delicate balance between extensive surgical
resections that potentially prolong survival (Jakola et al., 2012; Brown
et al., 2016; Stummer et al., 2008) while avoiding postoperative ad-
verse effects including new or worsened neurological deficits (De Witt
Hamer et al., 2012). Consequently, tumor location is one of the most
important factors for clinical decision making in glioma surgery, and
traditionally, brain regions that contain sensorimotor, visual and lan-
guage functions are considered so-called eloquent or more crucial to
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patient outcomes (Sawaya et al., 1998).
More specifically, neurosurgeons often pay extra attention to cor-
tical regions of the dominant (usually left) hemisphere, including the
inferior frontal lobe (Broca), superior temporal lobe (Wernicke), an-
gular gyrus, and the bilateral posterior frontal lobes (motor control of
dominant hand) (Sawaya et al., 1998; Sanai et al., 2008; Chang et al.,
2008). Surgeons also try to respect the medial occipital lobes (vision)
and to some degree the anterior parietal lobes (so-called parietal
functions) (Sawaya et al., 1998; Sanai et al., 2008; Chang et al., 2008).
In addition, major white matter tracts, including the pyramidal tracts,
the superior longitudinal fascicle (with the arcuate fascicle) and the
visual tracts are often respected (Sawaya et al., 1998; Essayed et al.,
2017; Witwer et al., 2002; Sanai and Berger, 2018; Hervey-Jumper and
Berger, 2016). Since maximal safe resection is the treatment goal of
surgery, various pre- and intraoperative methods are used to identify
these regions in an attempt to minimalize the risk for postoperative
neurological deficits and assumed subsequent reduction of quality of
life in patients (e.g. functional MRI, Diffusion Tensor Imaging (DTI),
navigated transcranial magnetic stimulation (nTMS), neuronavigation,
and direct cortical or subcortical stimulation) (De Witt Hamer et al.,
2012; Senft et al., 2011; Taylor and Bernstein, 1999; Nadkarni et al.,
2015; Frey et al., 2014; Unsgaard et al., 2006). However, methods
based on preoperative assessement are limited by intraoperative brain
shift and debatable reproducibility (Hill et al., 1998; Weng et al., 2018;
Wakana et al., 2007), and intraoperative methods are limited by no
agreed set-up, large practice variations, the potential for false stimu-
lation findings, and risk of intraoperative seizures (Szelenyi et al., 2010;
Kovac et al., 2016; Borchers et al., 2011). Also, awake surgery requires
intraoperative cooperation and is not suitable for all patients. Ad-
ditionally, not all brain functions are easy to monitor in an in-
traoperative setting. All together, the evidence for these surgical ad-
juncts is therefore generally rather low and direct comparisons across
methods are largely lacking.
While it is well known that lesions and surgery in the mentioned
eloquent areas may cause neurological symptoms and that identifica-
tion of these areas during surgery may reduce the risk of certain func-
tional deficits (De Witt Hamer et al., 2012; Sawaya et al., 1998) the
association between tumor location and patient-reported health-related
quality of life (HRQoL) has not been much explored. Presumably, there
are no non-functional areas in the brain, and since HRQoL is a complex
construct consisting of both physical, psychological and social domains,
it may provide valuable information as a supplement to neurological
function and functional anatomy (Katzan et al., 2017). Since it is as-
sessed from the patients perspectives, it accounts for the patient's own
subjective evaluation of health, which often differs substantially from
the judgment of health professionals (Slevin et al., 1988; Fisch et al.,
2003; Schiavolin et al., 2018). Thus, HRQoL evaluations are by defi-
nition relevant to patients, and more clinically important impairments
and changes may potentially be detected.
The relationship between lesion location and HRQoL has been ex-
plored in several studies, but with inconsistent results. In most studies
with larger study populations no relationship between lesion laterality/
affected lobes and HRQoL have been found (Cheng et al., 2010; Brown
et al., 2006; Polin et al., 2005; Sundseth et al., 2015), while some
studies report worse HRQoL scores in patients with lesions located in
specific areas (de Haan et al., 1995; Liu et al., 2009; Hahn et al., 2003;
Salo et al., 2002; Mainio et al., 2003; Moon et al., 2004). Possible ex-
planations of these contradictory findings are that different HRQoL
instruments have been used, that different study populations have been
studied, and that assessments have been done at different time points
during a specific disease course. Another likely explanation is that
many studies may suffer from variable external validity due to strict
inclusion criteria, limited sample sizes, small subgroups, and ill-defined
locations. Thus, the risk of false positive and negative findings may be
high. Traditionally, the impact of brain tumor location has also been
assessed by dichotomizing location into traditional anatomical regions
(e.g. lobes, gyri etc) and relating to dichotomous traditional functional
outcome (e.g. language problems yes/no, paresis yes/no). This may
introduce bias towards functional anatomical regions that are pre-
defined and towards functions that are easy to assess. Therefore, to
overcome some of the limitations from previous studies, location-spe-
cific maps with descriptive patient-reported data and defined quanti-
tative analyses may be a way to advance.
We hypothesized that brain regions associated with worse HRQoL
could be different from brain regions judged by clinicians as eloquent.
Using an explorative novel study approach in this setting, we have
developed an atlas for depicting and assessing the potential importance
of anatomical tumor location on perioperative generic HRQoL in pa-
tients with newly diagnosed high-grade glioma (HGG). In this atlas,
semi-automatically segmented 3D MRI images and patient-reported
data were merged into a standardized space, and the individual tumors
were given the values and color intensity of the corresponding HRQoL.
We hereby present the preliminary results from our prospective popu-
lation-based cohort.
2. Material and methods
2.1. Study population
In this prospective study, HGG-patients ≥18 years that were
scheduled for first-time surgical resections or diagnostic biopsies be-
tween January 2007 and December 2016 at St. Olavs Hospital,
Trondheim, Norway were eligible for inclusion. This department serves
a population of approximately 750,000 inhabitants as the single neu-
rosurgical department in a defined geographical catchment region. The
tumors were histopathologically classified by a neuropathologist based
on the 2007 WHO-classification (Louis et al., 2007), except those who
were diagnosed in the second half of 2016 and classified according to
the most recent WHO-classification (Louis et al., 2016). Patients with
missing preoperative MRIs, and multifocal/multicentric tumors were
excluded. Functional MRI and/or diffusion tensor imaging (DTI) were
performed preoperatively if deemed helpful. All patients underwent
surgery under general anesthesia, and a neuronavigation system in-
tegrating preoperative MRIs and intraoperative 3D ultrasound volumes
was routinely used (Gronningsaeter et al., 2000). After surgery, the
patients were referred to the oncological department for radiation and
concomitant and adjuvant chemotherapy according to the Stupp pro-
tocol (Stupp et al., 2005).
2.2. Data collection and variables
A HRQoL-questionnaire was completed 1–3 days before scheduled
surgery by the patient themselves, or with assistance from family or a
nurse. Postoperative follow-up was conducted by a study nurse in a
structured telephone interview with the patients at 4–6 weeks. Proxy
ratings were used if the patients had severe dysphasia or disabling
cognitive symptoms. These are found to be strongly correlated to pa-
tient-reported HRQoL (Brown et al., 2005; Sneeuw et al., 2002). To
assess HRQoL we used EQ-5D 3 L, which is a generic questionnaire
developed by the EuroQol Group (EuroQolGroup, 1990). It is widely
used in many health conditions, and validated in the Norwegian po-
pulation (Nord, 1991). The questionnaire consists of five single di-
mensions, including mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression. Each dimension has three levels: “no
problem”, “slight problem” or “major problem”, which give 243 pos-
sible combinations of responses that can be converted to a single global
index value. The index value was our primary outcome (i.e. “overall
HRQoL”), and range from −0,594 to 1, where 1 corresponds to perfect
health, 0 to death, and negative values are considered as worse than
death. We have previously demonstrated that the minimal clinically
important difference (MCID) for the EQ-5D index value is± 0.15 in
HGG-patients (Sagberg et al., 2014).
L.M. Sagberg et al. NeuroImage: Clinical 21 (2019) 101658
2
Patient and treatment characteristics including comorbidity
(Charlson et al., 1987) were collected from electronic medical records
in a prospectively maintained tumor registry. Karnofsky Performance
Status (KPS) was reported by the operating surgeon on a preoperative
questionnaire. Patient-reported new and/or worsened neurological
deficits after surgery were registered at follow-up, and postoperative
complications within 30 days were classified according to the Landriel
classification system (Landriel Ibanez et al., 2011). In addition, elo-
quence was estimated from preoperative MRI images as suggested by
Sawaya et al. (1998). According to this, we defined eloquent brain tu-
mors to be located in motor/sensory cortex, visual or speech center,
internal capsule, basal ganglia, hypothalamus/thalamus, brain stem
and/or dentate nucleus, while near-eloquent tumors were located near
these areas, including the corpus callosum.
2.3. Tumor segmentation
Preoperative 3D MRI images were obtained at admission using a 1.5
or 3 Tesla MRI scanner, including Siemens Skyra 3 T (n=60), Siemens
Avanto 1.5 T (n=51), Philips Intera 3 T (n=34), Siemens TrioTim 3 T
(n=11), Siemens Prisma 3 T (n=7), GE Signa Hdxt 1.5 T (n=2),
Siemens Symphony 1.5 T (n=2), Siemens Biograph 3 T (n=2) or
Philips Achieva 1.5 T (n=1). Two different software packages were
used for semi-automatic tumor segmentation: 3D Slicer version 4.3.1-
4.5.0 (3D Slicer, Boston, Massachusetts) (Fedorov et al., 2012) and
BrainVoyager version 1.2 (Brain Innovation, Maastricht, Netherlands).
In a recent study, we found high agreement in intra- and inter-rater
reliability using both these packages (Fyllingen et al., 2016). In total
130 MRI-images (77%) were segmented using 3D Slicer. The work-flow
for this software has previously described by others (Egger et al., 2013).
Remaining images (n=40, 23%) were segmented using BrainVoyager,
as described previously (Stensjoen et al., 2015). In both software
packages, T1-weighted images were used in contrast-enhancing lesions,
and the tumor was defined as the volume of pathological contrast-en-
hancement and necrotic tissue within the contrast-enhancing borders
(n=141). Fluid attenuation inversion recovery (FLAIR) images were
used in non-enhancing lesions (n=29). Median slice thickness in the
segmented images was 1mm (range 1 to 10). The segmentations were
performed by one of two authors (L.M.S., E.H.F) or a trained medical
student, and all segmentations were later verified by either a neuro-
surgeon (O.S) or a neuroradiologist.
2.4. Registration to a standardized space
The segmented MRI images were further brought into the Montreal
Neurological Institute (MNI) space, which is a standardized frame of
reference defined by the ICBM-152 brain template (Fonov et al., 2011;
Fonov et al., 2009). This atlas is the average of 152 young normal
brains and is available at http://nist.mni.mcgill.ca/. The segmented
images were spatially aligned with the average brain by intensity-based
image registration using the Advanced Neuroimaging Tools (ANT) re-
gistration toolkit (Avants et al., 2008) as part of the Nipype framework
(Gorgolewski et al., 2011). First, the individual images were pre-pro-
cessed (bias field correction (Tustison et al., 2010), intensity normal-
ization and resampling to 1mm3), and skull-stripped to exclude non-
brain structures using the brain mask included with the ICBM-152
template. Each image volume was then registered to the template using
affine and non-linear registration. During non-linear registration, the
segmented tumors were used to mask out the tumor region from the
estimation of the non-linear transformation. The resulting transforma-
tions were then applied to the individual tumor segmentations in order
to bring all the tumors into a common space. Two engineers performed
the data processing (D.H.I, I.R), and the pipeline can be downloaded at
https://github.com/Danielhiversen/NeuroImageRegistration. The in-
dividual tumors were further given the intensity of the corresponding
preoperative EQ-5D index value, and the postoperative change value.
All files were then converted and imported into the CustusX platform
(Askeland et al., 2016), were the colors and thresholds finally were
defined. Tumor locations were defined by using imported atlases of
lobes (Collins et al., 1999) and white matter tracts (Thiebaut de
Schotten et al., 2011). Lobes were classified according to where the
center of gravity in each tumor was located, while tumors that over-
lapped with any part of specific white matter tracts were classified as
involvement of these tracts.
2.5. Statistical analyses
The EQ-5D index values were calculated according to the EuroQol
scoring manual, using the UK time trade off (TTO) value set (Dolan,
1997). The calculations were impossible in seven patients due to
missing values in one or two subdomains, and these patients were
thereby included in subdomain analyses only. In the postoperative map,
the median change score was calculated in each voxel and values<
MCID±0.15 were considered as “unchanged”.
Both descriptive and defined quantitative analyses were done using
SPSS Statistics version 23.0 (IBM, Armonk, New York). Q-Q plots were
used to test for normal distribution of data. Mean ± SD was used if
data were normally distributed while median and range was used if
data were skewed and/or had significant outliers. For defined quanti-
tative analyses, independent samples t-test, Mann-Whitney U test,
Kruskal Wallis H-test, Pearson Chi-Square, and/or Fishers Exact test
were used to compare differences between groups. The statistical sig-
nificance level was set to P≤ .05, and all tests were two-sided. In a
power analyses for two independent samples, 41 patients in each group
were required (α=0.05, 1–β=0.8). Due to the use of non-parametric
tests, 15% were added, resulting in a total need of 47 patients in each
group. Mean differences and SD were obtained from a prior study
(Sagberg et al., 2014). For voxel-based lesion symptom mapping
(VLSM), the NiiStat toolbox for Matlab (www.nitrc.org/projects/
niistat) was used. Only voxels where at least ten patients had tumor
were included in the analysis. Age and lesion volume were included as
nuisance variables in the analysis. As our data were not normally dis-
tributed, the data were de-skewed using the square transform included
in NiiStat. Voxelwise statistical significance was determined by voxel-
based permutation thresholding (1000 permutations).
2.6. Ethics and approvals
All patients provided written, informed consent prior to enrollment
into the study. Data collection was approved by the Regional Ethical
Committee for Health Region Central-Norway, and adhered to guide-
lines of the Helsinki Declaration.
3. Results
3.1. Study population
A flow-chart of the inclusion process is shown in Fig. 1. In total, 170
(60%) of 285 eligible patients provided informed consent, filled out the
HRQoL-questionnaire and were included in the study. There were no
significant differences in age (P= .12), tumor volume (P= .20) or KPS
(P= .17) between included and excluded patients at baseline. Patients
with biopsy only were excluded from postoperative analyses and
follow-up data was available in 112 patients (82% of all resections).
Median follow up time was 36 days (range 24 to 70).
3.2. Baseline and treatment characteristics
Baseline and treatment characteristics are presented in Table 1. As
seen, 79% were functionally independent before surgery (i.e. KPS
≥70). The most common preoperative symptoms were cognitive
symptoms (42%), headache (38%), balance/coordination problems
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(34%), epileptic seizures (33%), and language problems (32%). Among
the 112 patients who underwent resections, moderate or severe com-
plications occurred in 12 patients (11%), while 26 (23%) reported new
or worsened neurological deficits after surgery.
3.3. Preoperative HRQoL
Axial images of the brain with preoperative overall HRQoL, tumor
volume and tumor distribution in patients with complete preoperative
EQ-5D questionnaires are presented in Fig. 2 and Video 1. Some “hot-
spots” with worse HRQoL are seen in the right primary sensorimotor
cortex, in the basal ganglia, and near the anatomical Wernicke's area,
arcuate fasciculus and the left hippocampus/amygdala. However, there
are few tumors in some of these locations, making the data less pow-
erful.
There were no statistically significant differences in preoperative
EQ-5D index values between patients with tumors in left or right
hemisphere, between tumors with the tumor center located in different
lobes, or between patients with tumors located in non-eloquent, near
eloquent or eloquent regions (Table 2). Using an additional white
matter tract atlas (Hammers et al., 2003), no difference in HRQoL be-
tween tumors in the central lobe (i.e. pre- and postcentral gyrus)
compared to other locations were observed (mean rank 69.17 vs. 83.9,
P= .18). Further, there was no significant difference for affection of
specific white matter tracts, except for patients with tumors involving
the internal capsule who reported significantly worse HRQoL scores
compared to patients without internal capsule involvement (mean rank
90.35 vs. 68.4, P= .004). When using VLSM methods to validate our
findings, no voxels survived the significance level (unthresholded maps
are presented in appendix (Fig. A1). The relationship between pre-
operative symptoms as registered from the medical journals and pre-
operative overall HRQoL was also explored. Significantly worse
HRQoL-scores were only found in patients with balance/coordination
problems (mean rank 70.69 vs. 87.61, P= .03) and motor symptoms
(mean rank 62.24 vs. 88.86, P= .002) compared to patients without
these symptoms.
As seen in Fig. 2, different tumor volumes are at diagnose rather
evenly distributed in the brain. However, tumors in the right hemi-
sphere were statistically larger (35.5mL vs. 29.7 mL, P= .03) and tu-
mors in the central lobe were significantly smaller compared to other
locations (median 15.2mL vs. 36.5 mL, P= .01). There was no corre-
lation between preoperative tumor volume and preoperative EQ-5D
Fig. 1. Flow chart of the inclusion process.
Table 1
Patient characteristics at baseline (N=170) and treatment characteristics after
resection (N=112).
Patient characteristics at baseline (N=170)
Age in years, mean (SD) 61 (± 12)
Female, n (%) 62 (37)
Preoperative Karnofsky Performance Status, n (%)
≥80 101 (59)
70 33 (19)
≤60 36 (21)
Charlson Comorbidity Index, n (%)
≥2 17 (10)
Preoperative symptoms, n (%)a
Headache 65 (38)
Seizures 56 (33)
Cognitive symptoms 71 (42)
Nausea 17 (10)
Balance/coordination problems 57 (34)
Visual disturbances 16 (9)
Language problems 54 (32)
Motor symptoms 45 (26)
Preoperative tumor volume in mL, median (range) 34.5 (0.1 to
210.1)
Histopathology, n (%)
Glioblastoma 133 (78)
Anaplastic astrocytoma or anaplastic oligodendroglioma 33 (19)
Unspecified high-grade glioma 4 (2)
Biopsy only, n (%) 34 (20)
Treatment characteristics after resection (N=112)
Gross total resection, n (%)b 35 (31)
Moderate or severe postoperative complications within
30 days, n (%)c
12 (11)
Postoperative new or worsened neurological deficits at
follow up, n (%)d
26 (23)
Initiation of adjuvant treatment within 30 days, n (%)
Radiotherapy 97 (87)
Chemotherapy 83 (74)
a Many patients had multiple symptoms.
b Based on postoperative MRI< 48 h. N=111 since one patient lacked an
early postoperative MRI.
c Grade II-III complications according to the Landriel classification system.
d Some patients had several deficits. N=111 since one patient lacked pa-
tient-reported deficits at follow up.
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index values (rs−0.073, P= .36) or postoperative change in EQ-5D
index values (rs − 0.046, P= .59).
For subitems of HRQoL, the most frequently reported preoperative
problems were for “activity”, “pain/discomfort” and “anxiety/depres-
sion” (Fig. 3). Statistically, laterality (right vs. left), involvement of
specific lobes, and eloquence was not related to “mobility”, “activity”,
“pain/discomfort” or “anxiety/depression” (Appendix, Tables A1–A5).
Tumor laterality and eloquence were not related to preoperative “self-
care”, while lobes were significantly related (P= .04). In a post-hoc
analysis we found that patients with tumors located in the right frontal
lobe reported significantly more problems with “self-care” than patients
with tumors located in other regions (32% vs. 16%, P= .03), and that
patients with tumors in the left temporal lobe reported significantly less
problems (3% vs. 23%, P= .007). Patients with tumor involvement in
the left uncinate fasciculus reported less problems with “mobility” (17%
vs. 40%, P= .02) while patients with tumors in the right uncinate
fasciculus reported less problems with “activity” (31% vs. 55%,
P= .02), and more problems with “anxiety/depression” (71% vs. 49%,
P= .03). Further, patients with tumor involvement in the internal
capsule reported more problems with “mobility” (53% vs. 25%,
P < .001), self-care (28% vs. 13%, P= .01) and “activity” (64% vs.
42%, P= .006), and patients with tumor involvement in the right
cingulum had more problems with “activity” (63% vs. 45%, P= .04).
3.4. Postoperative changes
Clinically important change in HRQoL after surgery was assessed in
patients who underwent surgical resection (Fig. 4, Video 2). Based on
the maps, it could seem like patients with tumors in or near the sen-
sorimotor cortex or harbouring deeper lesions affecting the pyramidal
tracts, the superior longitudinal fasciculus or the basal ganglia more
often reported change in HRQoL after surgery. However, statistically,
laterality, location in specific lobes, grading of eloquence, or tumor
locations overlapping specific white matter tracts were not predictive
factors of deterioration in HRQoL after surgery (Table 3). In post-hoc
analyses, deterioration in HRQoL was not more common in patients
with tumors in the central lobe (14% vs. 13%, P= .85), but patients
with new or worsened motor deficits after surgery more frequently
reported deterioration in HRQoL as compared to other patients (62% vs
25%, P= .001).
Fig. 2. Median preoperative EQ-5D index values in each voxel= yellow-red. Median preoperative tumor volume in each voxel= green. Number of tumors in each
voxel= blue. Scalar bars for each volume are shown at the right, and z-coordinates at the bottom. N=163. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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4. Discussion
Using an explorative novel study approach in this setting, we de-
veloped an atlas for depicting and assessing the potential importance of
tumor location for generic perioperative HRQoL in patients with newly
diagnosed HGG. We found that patient-reported overall HRQoL is ra-
ther evenly distributed across different tumor locations in the brain.
Anatomical “hotspots” were most often seen in regions with few lesions,
suggesting that these might reflect outliers. We found no statistical
difference in overall perioperative HRQoL between patients with tu-
mors in various lobes, in so-called eloquent areas, or in various voxels.
From the patients' perspective, there is no “dominant” hemisphere, and
except for the internal capsule, involvement of other major white
matter tracts was not associated with worse preoperative overall
HRQoL. Even though patients with preoperative motor symptoms re-
ported lower preoperative HRQoL, and although acquired motor defi-
cits were associated with worsened HRQoL after surgery, from pre-
operative MRI images we failed to identify specific neuroanatomical
regions that were predictive of perioperative deterioration of overall
HRQoL. The distinction between critical and less critical brain regions
seems thereby more unclear according to the patients than when judged
by physicians.
The relationship between lesion laterality/ affected lobes and
HRQoL has been explored in several studies, but with considerably
less detail and with inconsistent results. In accordance with our
findings most studies with larger study populations have not found
differences in HRQoL between patients with lesions in different re-
gions. Cheng et al. used a disease-specific HRQoL questionnaire in 92
patients with glioma, and did not find preoperative differences be-
tween patients with tumors in the left or right hemisphere, or among
tumors located in different lobes (Cheng et al., 2010). Similar find-
ings have also been reported for postoperative HRQoL in a large
oncological study (Brown et al., 2006), and in an even larger neu-
rosurgical sample where the relation between tumor location and
pre- and postoperative KPS was investigated (Polin et al., 2005). In
contrast, a weak association between right-sided stroke and lower
HRQoL has been found in 441 patients at 6 month follow up. How-
ever, in patients with high-grade gliomas such long-term HRQoL are
difficult to assess due to the progressive disease, multimodal treat-
ment and short life span. Also, functional reorganization and the
effects of rehabilitation are probably smaller. Interestingly, in a small
study of 65 patients with low-grade gliomas, patients with left-sided
tumors had worse physical well-being than patients with right-sided
tumors (Liu et al., 2009). Another small study also found more de-
pressive symptoms and memory problems in patients with tumors in
the left hemisphere (Hahn et al., 2003). Conversely, worse pre-
operative HRQoL have also been found in right-sided tumors, espe-
cially within the subdomains “pain”, “social isolation”, “emotion”
(Salo et al., 2002) and “anxiety” (Mainio et al., 2003). Patients with
strokes in the subcortical gray matter are also found to have lower
HRQoL (Moon et al., 2004).
Assuming that a certain symptom burden usually is needed before
being diagnosed with a brain tumor, and assuming that burden or
symptoms increase with tumor volume, a difference in tumor volume
between brain regions at diagnosis might indirectly reflect how im-
portant the region is to the patient. Accordingly, we detected right-
sided tumors to be significantly larger than tumors in the left hemi-
sphere, and tumors in the central lobe to be smaller. This might be
interpreted as an indirect sign of the left hemisphere being dominant
and supports the impression that motor functions are more critical.
However, deficits relating to motivation, cognition or emotions are
often more difficult to detect by patients than conventional neurologic
deficits such as language deficits.
We found more preoperative problems in some EQ-5D subdomains
for several specific locations. These were reported from patients with
tumors in motor and limbic related regions, especially if they were
Table 2
Preoperative EQ-5D index values versus tumor location, N=163.
n (%) Mean rank Median χ2 U df P
Laterality 3082.5 0.45
Left 86 84.66 0.80
Right 77 79.03 0.73
Lobes 9.08 8 0.34
Frontal left 32 (20) 75.59 0.71
Frontal right 31 (19) 79.15 0.73
Temporal left 35 (21) 92.97 0.80
Temporal right 28 (17) 83.52 0.80
Parietal left 15 (9) 89.30 0.74
Parietal right 12 (7) 86.21 0.73
Occipital right 1 (1) 95.00 0.80
Deep central left 4 (2) 67.00 0.62
Deep central
right
5 (3) 32.80 0.52
Grading of
eloquence
2.98 2 0.23
Non eloquent 42 (26) 84.26 0.78
Near eloquent 54 (33) 89.24 0.73
Eloquent 67 (41) 74.75 0.73
White matter tract involvementa
Arcuate
fasciculus left
2112.0 0.78
Yes 31 (19) 84.13 0.74
No 132 (81) 81.50 0.73
Arcuate
fasciculus
right
2182.0 0.68
Yes 36 (22) 79.11 0.73
No 127 (78) 82.82 0.73
Cingulum left 2779.0 0.55
Yes 44 (27) 85.66 0.78
No 119 (73) 80.65 0.73
Cingulum right 2441.0 0.35
Yes 46 (28) 76.57 0.73
No 117 (72) 84.14 0.73
Fornix and/or
corpus
callosum
3297.5 0.74
Yes 97 (60) 82.99 0.76
No 66 (40) 80.54 0.73
Uncinate left 2073.0 0.57
Yes 29 (18) 86.48 0.80
No 134 (82) 81.03 0.73
Uncinate right 1916.5 0.72
Yes 27 (17) 84.98 0.80
No 136 (83) 81.41 0.73
Optic radiations 1975.0 0.61
Yes 32 (20) 78.22 0.78
No 131 (80) 82.92 0.73
Inferior
longitudinal
fasciculus left
1300.5 0.98
Yes 18 (11) 81.75 0.76
No 145 (89) 82.03 0.73
Inferior
longitudinal
fasciculus
right
1115.5 0.19
Yes 19 (12) 68.71 0.62
No 144 (88) 83.75 0.73
Internal capsule 2288.0 0.004
Yes 62 (38) 68.40 0.69
No 101 (62) 90.35 0.80
χ2=Chi-square (Kruskal Wallis H test).
df=Degrees of freedom.
P= P-value. Bolded text indicates statistical significance.
U=Mann-Whitney U test.
a Overlap with tumor and white matter atlas data.
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located in the right hemisphere. Since the frontal lobe includes the
primary motor cortex, and the internal capsule consists of motor
pathways, more problems reported from patients in the objective sub-
domains seem logical. The cingulum area is related to motor control
and cognition (Paus, 2001), pain and emotion (Vogt, 2005), and other
symptoms like nausea (Napadow et al., 2013). This may explain activity
problems among patients with tumors in this tract. Further, although
the uncinate fasciculus is poorly understood, several others have found
an association between this pathway and anxiety, apathy and
depression (Hollocks et al., 2015; Phan et al., 2009), which is in
agreement with our findings.
The association between clinician-rated eloquence and HRQoL-
changes is difficult to explore due to patient selection, and since sur-
geons carefully attempt to avoid inflicting damage to these areas to
preserve neurological function. Also, judging which brain regions that
are eloquent based on structural preoperative MRI-images is difficult. In
a large validation study of a grading system for arteriovenous mal-
formations, eloquence scores varied between 28% and 60% in different
Fig. 3. Median preoperative problems in EQ-5D index subdomains in each voxel= yellow-red. Number of tumors in each voxel= blue. Scalar bars for each volume
are shown at the right, and z-coordinates at the bottom. N=170. (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of this article.)
L.M. Sagberg et al. NeuroImage: Clinical 21 (2019) 101658
7
centers (Kim et al., 2015). Thus, so-called eloquence assessments are
rather imprecise and subjective. Still, even though we did not find any
statistical difference in HRQoL between patients with tumors in elo-
quent, near eloquent or non-eloquent regions, the worse HRQoL scores
in patients with preoperative balance/coordination problems and
motor deficits, in patients with tumors involving the internal capsule,
and in patients with new or worsened motor deficits after surgery to-
gether indicate that motor deficits have a particularly profound impact
on several aspects of overall HRQoL as measured with EQ-5D, including
the subdomains “mobility”, “self-care”, and “usual activities”. From the
maps, it also seems like tumors located near motor and sensory cortex
had more deterioration in HRQoL after surgery. Thus, although sur-
geons and their patients may not necessarily agree on what are the most
crucial or eloquent brain regions, they seem to agree that motor control
is important. Preservation of motor functions may therefore be more
critical than other functions with respect to overall HRQoL. The lack of
motor control is perhaps more readily acknowledged by both the pa-
tients and their surgeons than for example personality changes or
milder cognitive deficits, at least in the perioperative phase of the
disease. Admittedly, assessment of other brain regions containing
functions like language or higher executive functions are more difficult
to assess in practice due to the inter-individual variation and the
complex and controversial localization of such functions.
Since the aim of HGG treatment is improved survival without jeo-
pardizing quality of life, potential factors influencing HRQoL should be
of particular interest. Compared to a functional status with only one
physical component like KPS, HRQoL is a multidimensional construct
that also includes physical, psychological and social aspects. It is as-
sessed from the patients' perspective, which often differs from the
clinicians' (Slevin et al., 1988). Thereby, it potentially represents a less
biased way of reporting and ensures relevance for the patients. Al-
though our intention was to explore the patients overall HRQoL, we
acknowledge that EQ-5D is not sensitive enough to capture all symp-
toms and facets of the disease. Thus, using a questionnaire focusing on
specific symptoms (e.g. language functions) may have yielded different
results. However, in our experience such extensive questionnaires are
frequently too burdensome and results in much missing data and con-
sequently selection bias, and is therefore often not applicable in an
unselected HGG population (Sagberg et al., 2016). A simple generic
questionnaire like EQ-5D is thereby a compromise between external
validity and sensitivity while maintaining the patients' perspectives on
HRQoL. Although it is a coarse measure, we believe it captures the most
significant problems caused by HGG. We have earlier found the ques-
tionnaire to be responsive for deterioration after glioma surgery
(Sagberg et al., 2014), it reflects the disease course over time (Sagberg
et al., 2016), and postoperative deterioration is associated with shorter
survival (Jakola et al., 2011).
Further development of our novel study approach with more pa-
tients and perhaps other patient-reported measures and/or neu-
ropsychological evaluations is a way to advance if aiming to assess true
Fig. 4. Median preoperative EQ-5D index values in each voxel= yellow-red. Median postoperative change in EQ-5D index value in each voxel= red-yellow-green
(values≤ ±0.15 are considered as unchanged). Number of tumors in each voxel= blue. Scalar bars for each volume are shown at the right, and z-coordinates at the
bottom. N=112. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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eloquent regions or functions as seen by the patients. Evidence-based
tools based on such maps could be useful to guide and support clinical
decision-making.
4.1. Strengths and limitations
HGG is a heterogeneous disease, and a major strength in the present
study is the population-based sample. However, detailed studies on the
impact of tumor location require a considerable sample size, and our
findings are therefore presented as preliminary. Admittedly, our sample
size is still rather large in this setting, and our negative statistical
findings are validated by using VLSM-methods that take the distribution
of data into account. Further, although the reliability of our segmen-
tations is found to be acceptable (Fyllingen et al., 2016), finding the
exact pathological border of a tumor during segmentation is an im-
possible task due to the diffuse growth pattern of glioma. Not only the
focal tumor volume, but also the effect of edema, the anatomical and
functional variability, and possible remote effects may influence the
HRQoL in different brain regions. On the other hand, functional re-
organization and brain plasticity is probably limited due to the fast-
growing biology. In addition, the registration to the average brain, and
the use of imported atlases of lobes and white matter tracts may con-
tribute to inaccuracy. However, detailed assessment of all major func-
tional regions and all white matter tracts is impossible on the individual
level. Other limitations are the possibility of false negative findings in
regions with few or none tumors (e.g. visual cortex), and the risk of
false positive findings when making multiple tests. Finally, of 112 pa-
tients, 25 (22%) had the best possible score at baseline, indicating a
ceiling effect (McHorney and Tarlov, 1995), which could conceal po-
tential improvements after surgery.
5. Conclusions
In this ongoing registry-based project we found that median patient-
reported HRQoL is rather evenly distributed across different tumor lo-
cations in the brain. The impact of anatomical tumor location on overall
perioperative HRQoL therefore seems lower than frequently believed.
However, worse HRQoL was found in patients with tumors in motor
related regions, indicating that these areas are crucial also from the
patients' perspective. Evidence-based tools based on maps could be a
useful adjunct to physician-rated experience-based eloquence assess-
ments to guide and support clinical decision-making in neurosurgery.
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Table 3
Crosstabulation of postoperative deterioration in EQ-5D index values and tumor
location, N=112.
Postoperative deterioration (≥MCID)
Yes, n
(%)
No, n (%) χ2 or F df P
Laterality 0.30 1 0.58
Left 14 (23) 47 (77)
Right 14 (28) 37 (73)
Lobes 5.40 0.60
Frontal left 6 (26) 17 (74)
Frontal right 4 (19) 17 (81)
Temporal left 7 (26) 20 (74)
Temporal right 6 (29) 15 (71)
Parietal left 1 (13) 7 (88)
Parietal right 4 (57) 3 (43)
Deep central left 0 (0) 3 (100)
Deep central right 0 (0) 2 (100)
Grading of eloquence 0.70 2 0.70
Non eloquent 8 (23) 27 (77)
Near eloquent 10 (30) 23 (70)
Eloquent 10 (23) 34 (77)
White matter tract involvementa
Arcuate fasciculus left 2.92 1 0.09
Yes 2 (10) 18 (90)
No 26 (28) 66 (72)
Arcuate fasciculus right 0.08 1 0.78
Yes 6 (27) 16 (73)
No 22 (24) 68 (76)
Cingulum left 0.08 1 0.78
Yes 5 (23) 17 (77)
No 23 (26) 67 (74)
Cingulum right 0.02 1 0.90
Yes 7 (26) 20 (74)
No 21 (25) 64 (75)
Fornix and/or corpus callosum 0.98 1 0.32
Yes 18 (29) 45 (71)
No 10 (20) 39 (80)
Uncinate left 0.49 1 0.49
Yes 4 (19) 17 (81)
No 24 (26) 67 (74)
Uncinate right 1.00
Yes 4 (24) 13 (77)
No 24 (25) 71 (75)
Optic radiations 0.02 1 0.89
Yes 6 (26) 17 (74)
No 22 (25) 67 (75)
Inferior longitudinal fasciculus
left
0.76
Yes 3 (19) 13 (81)
No 25 (26) 71 (74)
Inferior longitudinal fasciculus
right
0.52
Yes 5 (33) 10 (67)
No 23 (24) 74 (76)
Internal capsule 0.06 1 0.81
Yes 8 (24) 26 (77)
No 20 (26) 58 (75)
χ2=Pearsons chi-square.
MCID=Minimal Clinically Important Difference≥0.15.
F= Fishers Exact test.
df=Degrees of freedom.
P=P-value. Bolded text indicates statistical significance.
a Overlap with tumor and white matter atlas data.
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